These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33230821)

  • 1. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.
    Dai CH; Zhu LR; Wang Y; Tang XP; Du YJ; Chen YC; Li J
    J Cell Physiol; 2021 Jun; 236(6):4538-4554. PubMed ID: 33230821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction.
    Li XQ; Ren J; Wang Y; Su JY; Zhu YM; Chen CG; Long WG; Jiang Q; Li J
    Cell Oncol (Dordr); 2021 Feb; 44(1):135-150. PubMed ID: 32936421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
    Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
    Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
    Xiang M; Jiang HG; Shu Y; Chen YJ; Jin J; Zhu YM; Li MY; Wu JN; Li J
    Int J Biol Sci; 2020; 16(9):1536-1550. PubMed ID: 32226300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer.
    Park J; Purushothaman B; Hong S; Choi M; Jegal KH; Park M; Song JM; Kang KW
    Life Sci; 2024 Jul; 348():122681. PubMed ID: 38697281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways.
    Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P
    Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.
    Zhang Q; Chen M; Cao L; Ren Y; Guo X; Wu X; Xu K
    Mol Carcinog; 2020 Jun; 59(6):590-603. PubMed ID: 32189414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
    Wang Y; Liu Q; Chen H; You J; Peng B; Cao F; Zhang X; Chen Q; Uzan G; Xu L; Zhang D
    Anticancer Drugs; 2018 Sep; 29(8):748-755. PubMed ID: 29927769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
    Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation.
    Zhang X; Huang C; Cui B; Pang Y; Liang R; Luo X
    Dis Markers; 2021; 2021():5530673. PubMed ID: 34122668
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.